MediPharm Labs Corp.

Supplying Canada with Pharma-Grade Cannabis

This profile is part of a paid investor education campaign.*


MediPharm Labs Corp. (TSX:LABS, OTCQX:MEDIF, FSE:MLZ) is a leading B2B specialized Canadian cannabis extractor, producing purified pharma-grade cannabis oil and concentrates for the development of cannabinoid derived products. As part of their B2B model, MediPharm Labs supplies raw materials, formulations, processing and packaging for ready-to-sell advanced derivative products.

The first Canadian company to become a licensed producer of cannabis oil under the Access to Cannabis for Medical Purposes Regulations (ACMPR) without being a licensed cultivator, MediPharm Labs is focused on bringing pharma-grade products to the adult-use and medical cannabis industries in Canada. The company expects to receive its license to extract and import medical cannabis products in Australia and to have its facility operational in Australia in the near term(Q2 2019).

Company Highlights

  • Primarily focused on producing pharma-grade cannabis oil and concentrates.
  • Named Cannabis Start-Up of the Year at the 2018 Canadian Cannabis Awards by LIFT&Co.
  • Wholly-owned 70,000-square-foot facility has been constructed to EU GMP standards with ISO rated clean rooms, and is operational.
  • Pharma-grade critical environments, methodologies and discipline result in repeatability in manufacturing.


*Disclaimer: The profile provides information which was sourced and approved by MediPharm Labs in order to help investors learn more about the company. MediPharm Labs  is a client of the Investing News Network (INN). The company’s campaign fees pay for INN to create and update this profile page, to which links are placed on and channel newsletters.

The company description, investment highlights and catalysts were sourced by INN and approved by the company. INN does not guarantee the accuracy or thoroughness of the information contained on this page.

INN does not provide investment advice and the information on profile should not be considered a recommendation to buy or sell any security.

INN does not endorse or recommend the business, products, services or securities of any company profiled.

Readers should conduct their own research for all information publicly available concerning the company.